vs

Side-by-side financial comparison of APTARGROUP, INC. (ATR) and Edwards Lifesciences (EW). Click either name above to swap in a different company.

Edwards Lifesciences is the larger business by last-quarter revenue ($1.6B vs $982.9M, roughly 1.7× APTARGROUP, INC.). Edwards Lifesciences runs the higher net margin — 23.1% vs 7.4%, a 15.7% gap on every dollar of revenue. On growth, Edwards Lifesciences posted the faster year-over-year revenue change (16.7% vs 10.8%). Over the past eight quarters, Edwards Lifesciences's revenue compounded faster (9.7% CAGR vs 3.9%).

AptarGroup, Inc., also known as Aptar, is a United States–based global manufacturer of consumer dispensing packaging and drug delivery devices. The group has manufacturing operations in 18 countries.

Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the Sapien transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter.

ATR vs EW — Head-to-Head

Bigger by revenue
EW
EW
1.7× larger
EW
$1.6B
$982.9M
ATR
Growing faster (revenue YoY)
EW
EW
+5.9% gap
EW
16.7%
10.8%
ATR
Higher net margin
EW
EW
15.7% more per $
EW
23.1%
7.4%
ATR
Faster 2-yr revenue CAGR
EW
EW
Annualised
EW
9.7%
3.9%
ATR

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
ATR
ATR
EW
EW
Revenue
$982.9M
$1.6B
Net Profit
$72.8M
$380.7M
Gross Margin
78.0%
Operating Margin
10.9%
1.8%
Net Margin
7.4%
23.1%
Revenue YoY
10.8%
16.7%
Net Profit YoY
-7.5%
6.8%
EPS (diluted)
$1.12
$0.66

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ATR
ATR
EW
EW
Q1 26
$982.9M
$1.6B
Q4 25
$962.7M
$1.6B
Q3 25
$961.1M
$1.6B
Q2 25
$966.0M
$1.5B
Q1 25
$887.3M
$1.4B
Q4 24
$848.1M
$1.4B
Q3 24
$909.3M
$1.4B
Q2 24
$910.1M
$1.4B
Net Profit
ATR
ATR
EW
EW
Q1 26
$72.8M
$380.7M
Q4 25
$74.3M
$91.2M
Q3 25
$127.9M
$291.1M
Q2 25
$111.7M
$333.2M
Q1 25
$78.8M
$358.0M
Q4 24
$100.9M
$385.6M
Q3 24
$100.0M
$3.1B
Q2 24
$90.5M
$366.3M
Gross Margin
ATR
ATR
EW
EW
Q1 26
78.0%
Q4 25
78.1%
Q3 25
77.8%
Q2 25
77.5%
Q1 25
78.7%
Q4 24
78.9%
Q3 24
80.6%
Q2 24
79.9%
Operating Margin
ATR
ATR
EW
EW
Q1 26
10.9%
1.8%
Q4 25
11.0%
9.6%
Q3 25
14.2%
19.8%
Q2 25
14.9%
26.8%
Q1 25
12.8%
27.9%
Q4 24
14.2%
22.6%
Q3 24
15.2%
25.9%
Q2 24
13.8%
26.8%
Net Margin
ATR
ATR
EW
EW
Q1 26
7.4%
23.1%
Q4 25
7.7%
5.8%
Q3 25
13.3%
18.7%
Q2 25
11.6%
21.7%
Q1 25
8.9%
25.3%
Q4 24
11.9%
27.8%
Q3 24
11.0%
226.7%
Q2 24
9.9%
26.7%
EPS (diluted)
ATR
ATR
EW
EW
Q1 26
$1.12
$0.66
Q4 25
$1.13
$0.16
Q3 25
$1.92
$0.50
Q2 25
$1.67
$0.56
Q1 25
$1.17
$0.61
Q4 24
$1.48
$0.65
Q3 24
$1.48
$5.13
Q2 24
$1.34
$0.61

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ATR
ATR
EW
EW
Cash + ST InvestmentsLiquidity on hand
$229.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$2.6B
Total Assets
$5.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ATR
ATR
EW
EW
Q1 26
$229.5M
Q4 25
$409.5M
$4.2B
Q3 25
$264.8M
$3.8B
Q2 25
$169.8M
$4.1B
Q1 25
$136.8M
$3.9B
Q4 24
$226.2M
$4.0B
Q3 24
$327.9M
$4.4B
Q2 24
$223.9M
$2.0B
Total Debt
ATR
ATR
EW
EW
Q1 26
Q4 25
$1.1B
Q3 25
$546.0M
Q2 25
$535.1M
Q1 25
$561.2M
Q4 24
$688.1M
Q3 24
$822.7M
Q2 24
$681.5M
Stockholders' Equity
ATR
ATR
EW
EW
Q1 26
$2.6B
Q4 25
$2.7B
$10.3B
Q3 25
$2.8B
$10.2B
Q2 25
$2.7B
$10.5B
Q1 25
$2.5B
$10.1B
Q4 24
$2.5B
$10.0B
Q3 24
$2.5B
$9.5B
Q2 24
$2.4B
$7.4B
Total Assets
ATR
ATR
EW
EW
Q1 26
$5.1B
Q4 25
$5.3B
$13.7B
Q3 25
$5.1B
$13.3B
Q2 25
$4.9B
$13.5B
Q1 25
$4.5B
$13.0B
Q4 24
$4.4B
$13.1B
Q3 24
$4.6B
$13.0B
Q2 24
$4.5B
$10.1B
Debt / Equity
ATR
ATR
EW
EW
Q1 26
Q4 25
0.43×
Q3 25
0.20×
Q2 25
0.20×
Q1 25
0.22×
Q4 24
0.28×
Q3 24
0.32×
Q2 24
0.28×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ATR
ATR
EW
EW
Operating Cash FlowLast quarter
Free Cash FlowOCF − Capex
$53.3M
FCF MarginFCF / Revenue
5.4%
Capex IntensityCapex / Revenue
6.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$327.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ATR
ATR
EW
EW
Q1 26
Q4 25
$183.7M
$450.9M
Q3 25
$177.6M
$573.7M
Q2 25
$126.0M
$290.2M
Q1 25
$82.7M
$280.4M
Q4 24
$178.2M
$-127.5M
Q3 24
$229.3M
$351.8M
Q2 24
$143.6M
$371.5M
Free Cash Flow
ATR
ATR
EW
EW
Q1 26
$53.3M
Q4 25
$96.9M
$353.5M
Q3 25
$114.3M
$516.2M
Q2 25
$62.5M
$240.9M
Q1 25
$25.9M
$224.4M
Q4 24
$112.2M
$-177.3M
Q3 24
$162.7M
$299.9M
Q2 24
$75.4M
$286.1M
FCF Margin
ATR
ATR
EW
EW
Q1 26
5.4%
Q4 25
10.1%
22.5%
Q3 25
11.9%
33.2%
Q2 25
6.5%
15.7%
Q1 25
2.9%
15.9%
Q4 24
13.2%
-12.8%
Q3 24
17.9%
22.1%
Q2 24
8.3%
20.9%
Capex Intensity
ATR
ATR
EW
EW
Q1 26
6.7%
Q4 25
9.0%
6.2%
Q3 25
6.6%
3.7%
Q2 25
6.6%
3.2%
Q1 25
6.4%
4.0%
Q4 24
7.8%
3.6%
Q3 24
7.3%
3.8%
Q2 24
7.5%
6.2%
Cash Conversion
ATR
ATR
EW
EW
Q1 26
Q4 25
2.47×
4.94×
Q3 25
1.39×
1.97×
Q2 25
1.13×
0.87×
Q1 25
1.05×
0.78×
Q4 24
1.77×
-0.33×
Q3 24
2.29×
0.11×
Q2 24
1.59×
1.01×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons